Pegylated Interferon Alfa 2a
Mostrando 1-3 de 3 artigos, teses e dissertações.
1. Alternativas de tratamento para hepatite viral crônica B: análise de custo-efetividade
Introduction: Hepatitis B is one of the most common infectious diseases worldwide and has been showing increasing expenditures in the Brazilian Unified Healh System (SUS). Objectives: To perform a pharmacoeconomic and epidemiological evaluation of interferon and lamivudine classified as high costs in SUS and utilized for the treatment of adults with chronic
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 17/02/2011
2. Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil
The treatment of chronic hepatitis C (CHC) with peginterferon alpha-2b/ribavirin (PegIFN + Rib) produced larger sustained viral response (SVR) compared to the conventional (non-pegylated) interferon/ribavirin (IFN + Rib), but its cost-effectiveness was not assessed in Brazil. We developed a Markov model to mirror the natural disease history and cohorts of pa
Brazilian Journal of Infectious Diseases. Publicado em: 2009-06
3. Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?
The combination of pegylated interferon (PEG-INF) and ribavirin is currently the best treatment for chronic hepatitis C, providing a sustained virological response (SVR) in 54%-63% of patients. In patients infected with hepatitis C virus (HCV) genotype 1, the SVR rate is 42%-52%. To evaluate the treatment efficacy of this drug combination, we conducted an op
Brazilian Journal of Infectious Diseases. Publicado em: 2007-12